Lupin, Mark Cuban’s Cost Plus Drugs and COPD Foundation boost COPD treatment access

In a significant healthcare development, global pharmaceutical giant Lupin Limited (Lupin) has entered into a groundbreaking collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) and the COPD Foundation. This collaboration aims to enhance healthcare access by expanding the availability of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, for COPD patients in the US. The inhalation powder is currently the only generic product available that is therapeutically equivalent to Spiriva HandiHaler by Boehringer Ingelheim Pharmaceuticals, Inc.

Chronic obstructive pulmonary disease (COPD) is a pervasive health issue in the US, affecting over 15 million adults and ranking as the fourth leading cause of death in the country. This collaboration represents a landmark effort to address the unmet needs in COPD treatment and to ease the disease burden.

Spiro Gavaris, President US Generics at Lupin, emphasized the importance of the collaboration: “As a leading healthcare organization, we are committed to increasing access for patients seeking treatment options for respiratory conditions like COPD. Our collaboration with Mark Cuban Cost Plus Drug Company and the COPD Foundation reinforces our commitment to offering quality treatment options to patients.”

Mark Cuban Cost Plus Drug Company’s CEO, Alex Oshmyansky, also highlighted the shared mission among the collaborators. “All three organizations share a common goal of providing consumers the lowest possible price for their prescription medication. With Cost Plus Drugs, consumers can have the convenience of medication mailed directly to their homes at a fair price.”

Jean Wright, CEO of the COPD Foundation, added, “Accessible and affordable medications are vital for a healthier, more empowered life for COPD patients. A generic option like the one provided by this collaboration ensures that vital treatments remain within reach for patients, alleviating financial strain.”

With COPD affecting millions and posing a significant public health challenge, this collaboration between Lupin, Mark Cuban Cost Plus Drug Company, and the COPD Foundation represents a monumental step in making essential treatments more accessible and affordable. It serves as a cornerstone in the collective endeavor to improve healthcare outcomes for COPD patients in the US.